Cryoport reports second quarter 2025 financial results

Second quarter revenue increased 14% year-over-year to $45.5 million commercial cell & gene therapy revenue increased 33% year-over-year to $8.7 million life sciences services revenue rose 21% year-over-year, including a 28% increase in biostorage/bioservices revenue launched strategic partnership agreement with the dhl group; closed cryopdp divestiture company reaffirms full year 2025 revenue guidance of $165 to $172 million nashville, tenn. , aug. 5, 2025 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport" or the "company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (q2) and first half (h1) of 2025.
CYRX Ratings Summary
CYRX Quant Ranking